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Introduction
The 1972 case of Canterbury v Spence [1]
ranks among the best-known court deci-
sions in American and international health
law. Mr Canterbury, a 19-year-old typist
for the Federal Bureau of Investigation,
became paraplegic and incontinent follow-
ing spinal surgery. He sued, alleging that
the surgeon, Dr Spence, had failed in his
duty to outline the risks of this outcome.
Dr Spence countered that he owed no
duty to warn of such an unexpected
complication. The enduring significance
of the case lies in the decision by the
District of Columbia Court of Appeals to
reject the traditional customary standard
for assessing negligence (what would a
reasonable practitioner have done?), and opt
instead for a new patient-centered stan-
dard (what would a reasonable patient want to
know?).
In the 40 years since Canterbury, appellate
courts of many US states [2] and many
countries—including the United Kingdom
[3], Canada [4], Australia [5], Malaysia
[6], Ireland [7], and New Zealand [8]—
have considered similar cases, disputes in
which patients and doctors square off over
whetheraparticulartreatmentriskoughtto
have been disclosed. (Descriptions of these
cases are provided in Table S1.) Many
jurisdictions have moved toward legal
standards for risk disclosure that prioritise
patient preferences. This general shift
compounds an uncertainty that doctors,
especially surgeons, regularly face: which
types of risks should be emphasized in the
consent process?
While the duty to disclose risks has
been analysed and critiqued extensively
in the health law and bioethics literature
[9], this scholarship is largely normative
[10]. Remarkably little is known about
the clinical circumstances in which doc-
tors and patients disagree about whether
a particular risk ought to have been
disclosed (‘‘disputed duty cases’’).
We identified 481 legal disputes over
informed consent to medical treatment in
Australia. The disputes were drawn sys-
tematically from litigation and conciliation
files resolved over a seven-year period. In
a recent report [11] we described general
characteristics of this sample. In this
analysis, we describe a subset that involved
explicit disagreements between patients
and doctors about whether a particular
risk ought to have been disclosed. Our aim
was to detail the treatments, risks, and
adverse outcomes at issue in these cases.
Analysis
Setting
Avant Mutual Group Limited (Avant)
and the Office of the Health Services
Commissioner of Victoria (HSC) provided
data for our anlaysis. Avant is Australia’s
largest provider of medical indemnity
insurance, covering approximately 55%
of the country’s registered medical practi-
tioners. The HSC, established in 1987, has
statutory responsibility for resolving com-
plaints against health care providers in
Victoria, Australia’s second most populous
state with 5.2 million residents. Patients
must initiate complaints in writing but do
not require legal representation. The
system is free and open to all and is
advertised widely in health care facilities.
Data
The sample frame consisted of all
malpractice claims (n=7,846) brought
against doctors insured by Avant in three
states (New South Wales, Victoria, and
Queensland) between 1 January 2002 and
31 December 2008, and all conciliated
complaints (n=1,898) lodged with the
HSC in Victoria during the same period.
(The HSC data related to all complaints
against doctors, regardless of who insured
them.) We have previously described our
method for screening claims and com-
plaints in this sample frame to determine
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informed consent dispute [11]. We recap
definitions of key terms in Box 1.
Data collection proceeded in two steps.
We first undertook an initial review of
cases in the parent study [11] and then
followed up with an in-depth review
reported here. In the follow-up review,
one investigator (MMB) returned to Avant
and HSC offices between August and
November 2010 and re-examined the
hardcopy files associated with all cases
flagged in the initial review as meeting the
study definition of a disputed duty case.
We confirmed that the cases met the study
definition and collected supplementary
information, including details of patients’
allegations and health outcomes, doctors’
responses, and the undisclosed risks in
dispute. Probabilities associated with the
clinical risks in selected cases were subse-
quently obtained through a series of
Medline searches and literature reviews
(one per case).
We did not attempt to judge whether
the patient’s or doctor’s position in the
disputed duty cases was the correct one.
Doing so would have required more
information than was available to us in
the case files. The case outcomes are not
an appropriate proxy for merit. With
claims, cases were typically resolved
by out-of-court negotiation. Moreover,
allegations about deficiencies in the con-
sent process often co-existed with other
types of allegations, yet legal outcomes
were generally ‘‘global’’, not tethered to
specific allegations. With complaints, the
HSC runs a dispute resolution process; it
generally does not rule on the merit of
patients’ allegations or practitioners’ re-
sponses.
The ethics committee at the University
of Melbourne approved the study.
Findings
Frequency of Disputed Duty Cases
A total of 3.4% (263/7,846) of malprac-
tice claims and 11.5% (218/1,898) of
conciliated complaints involved disputes
over informed consent. Three-quarters
(375/481) of informed consent disputes
involved allegations that risks had not
been disclosed (Figure 1). However, most
of these cases (88%, 330/375) were not
disputed duty cases because they did not
involve disagreements between patients
and clinicians over whether a risk ought
to have been disclosed.
Rather, factual disagreements predom-
inated. These were chiefly factual disputes
about whether the risk had been disclosed
before treatment (e.g., ‘‘I would have
discussed the risks of thrombosis associated
with this contraceptive’’) or whether the
patient’s poor outcome was due to materi-
alisation of the undisclosed risk (e.g.,
‘‘There was no causal connection between
the iodine discogram and her thyroid
disease’’). In addition, in several cases the
doctor conceded that the risk was not
disclosed but should have been (e.g., ‘‘I
didn’t disclose the risk of bile duct injury. I
apologise for this and think the case should
be settled.’’).
Nine percent (45/481) of informed
consent cases were disputed duty cases.
All findings reported hereafter pertain to
this special group of cases.
Treatments and Adverse Outcomes
In more than two-thirds of disputed
duty cases, the treatment rendered was a
surgical procedure (31/45). The rest
involved medications (7), anaesthetic pro-
cedures (3), obstetric care (3), and a
washout of tear ducts performed by a
general practitioner.
Table 1 shows the types of adverse
outcomes for patients that resulted from
materialisation of the undisclosed risks. In
a third of cases (15/45), patients com-
plained of not being warned of the risk
that further surgery would be needed; in
nearly three-quarters of cases (33/45) the
complaint centered on not being warned
about one of four outcomes: chronic pain,
impaired vision or hearing, poor cosmetic
result, and infertility or sexual dysfunction.
The dominance of these five outcomes
among disputed duty cases is striking:
collectively, they featured in 84% of
Summary Points
N Doctors, especially surgeons, are often unsure which clinical risks they should
disclose and discuss with patients before treatment. Leading medical
malpractice cases in many countries have centered on this issue.
N In a sample of nearly 10,000 malpractice claims and conciliated health care
complaints from Australia, we identified 481 disputes over informed consent, 45
(9%) of which were ‘‘disputed duty cases’’—disagreements between patients
and doctors over whether a particular clinical risk should have been disclosed
before treatment.
N Two-thirds of disputed duty cases involved surgical procedures, and the
majority (38/45) of cases related to five adverse outcomes: the need for further
surgery, poor cosmetic result, impaired vision or hearing, chronic pain, and
infertility or sexual dysfunction.
N The most common justifications doctors gave for non-disclosure were that the
risk was too rare to warrant discussion or the specific risk was covered by a
more general risk that was discussed.
N Although most informed consent disputes appear to involve disagreements
about who said what and when, not stand-offs over whether a particular risk
ought to have been disclosed, doctors may routinely underestimate the
importance of a small set of risks that vex patients.
Box 1. Key Definitions
A claim is a written demand for compensation.
A conciliated complaint is a complaint the HSC considers too complex or serious
to be resolved through facilitated communication alone, and so refers it to formal
conciliation. (Approximately 20% of all complaints lodged with the HSC proceed
to conciliation.)
An informed consent dispute is a claim or complaint that alleges a deficiency,
either in the quality or quantity of information provided to the patient about a
treatment prior to a decision about whether to undertake it, or in the process
through which the patient was asked to consider such information and make a
decision.
A disputed duty case is a type of informed consent dispute, one that involves a
head-to-head disagreement between a patient and a doctor over the need to
explain certain risks. These are situations in which a patient (or the patient’s
representative) alleges that a particular risk should have been disclosed before
treatment, and a doctor responds that the disclosure was unnecessary or
inappropriate.
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that several of the leading court cases,
detailed in Table S1, involved this same
group of outcomes.) What these outcomes
have in common is important quality-of-
life implications for patients. Our findings
suggest that doctors may underestimate
the premium patients place on under-
standing the risks of them in advance of
treatment.
The adverse outcomes enumerated in
Table 1 are essentially physical in nature.
Patients in approximately a third of cases
(17/45) also alleged psychological harm, in
the form of depression or an anxiety
disorder, associated with the adverse
outcome.
Doctors’ Justifications for Non-
Disclosure
Table 2 shows the distribution of cases
by type of justification doctors gave for
not having disclosed the risk. Examples
of selected cases are also shown. The
‘‘risk too rare’’ and ‘‘subset of general
risk’’ justifications for non-disclosure
were particularly common; collectively,
they appeared in nearly two-thirds of the
disputed duty cases.
Risk too rare. The most common
justification for non-disclosure (18/45
cases) was that the risk was too rare.
These were cases in which doctors argued
that the outcome the patient experienced
occurs too infrequently in clinical practice
to warrant disclosing it during the
informed consent process, or the risk was
so rare that it was unknown to the doctor.
General risk was disclosed. The
next most common justification (11/45
cases) was that the risk not discussed was
encapsulated in a general risk that was
discussed. In a quarter of cases, for
example, the doctor mentioned generic
risks such as bleeding or infection without
providing specific information regarding
possible consequences for the patient. In
another case, a doctor had warned the
patient of the risk of an allergic reaction to
phenytoin, but had not specifically
mentioned the risk of Stevens-Johnson
syndrome and blindness. These findings
are consistent with research suggesting
that clinicians tend to be overly general
in their descriptions of some risks, and
struggle with discussing serious
complications in specific terms [12].
Other justifications. Each of the
other types of justification applied to
relatively few cases. Doctors defended
non-disclosure in five cases by arguing
that the risk was obvious and a reasonable
patient ought to have been aware of it. In
four cases, the doctor argued it was
sufficient to have advised the patient of
the average recovery time for a procedure
and been silent on risks of delayed
recovery; all of these cases involved
cosmetic procedures.
Doctors in a further four cases argued
that the need for disclosure was obviated
by the fact that the benefits of the
treatment clearly outweighed any risks,
and disclosing the risk in question would
have imposed an unnecessary burden on
the patient; all of these cases involved
surgical procedures. Arguments that it is
unnecessary or inappropriate to ‘‘burden’’
the patient with information about proce-
dures they are about to undergo are
paternalistic; they hark back to an earlier
era in which there was greater deference
to the medical profession, and such
exercises of ‘‘therapeutic privilege’’ were
common and accepted [13,14].
The final three cases were unusual in
that the adverse outcome was patently due
to negligent care. The patients in these
cases alleged a failure to warn of the risk of
the outcome and the doctors argued the
risk was not one they needed to disclose.
(Technically, the doctors were probably
correct, because there is no legal duty to
warn of risks arising from negligent care.)
Rare Risk Cases
Table 3 provides details of the treat-
ments, adverse outcomes, and risk proba-
bilities for the 18 disputed duty cases in
which the doctors’ justification for non-
disclosure was that the risk was too rare to
warrant it. Our literature review indicated
a wide span in these probabilities, ranging
from complications described in only a few
case reports (e.g., testicular loss following
varicocoele repair) to well-recognised ad-
verse outcomes occurring in over 1% of
cases (e.g., fetal laceration during caesar-
ean delivery of a breech baby).
There was no obvious pattern to this
wide variability. We had expected an
inverse correlation between risk frequency
and severity in this group of cases, but
Figure 1. Derivation of study sample.
doi:10.1371/journal.pmed.1001283.g001
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evidence of convergence on a standard risk
threshold: the probabilities appeared to
vary across several orders of magnitude,
from less than 0.01% to greater than 1%.
Discussion
Disputed Duty Cases in Context
Landmark court battles [1,3,4,5,6,7,8]
over informed consent have centred on
what legal standard of care should apply in
head-to-head disputes between patients
and doctors over whether a treatment risk
warrants disclosure. To the best of our
knowledge, this is the first study to
examine this type disagreement at the
population level. The finding that nine out
of ten legal disputes over informed consent
cases did not turn on such a disagreement
highlights a general point: highly publi-
cized legal cases—those at the apex of the
‘‘dispute pyramid’’—can easily distort
understanding of the much larger number
of ‘‘garden variety’’ disputes and grievanc-
es that sit beneath them [15,16].
The finding also has a practical message
for practicing clinicians: malpractice claims
and complaints over informed consent are
not uncommon events, but when they arise
they are most likely to centre on mundane
factual disagreement over who said what
and when, not contests over what should
have been disclosed. This underscores that
for the informed consent process, like most
other areas of clinical practice, regular and
careful documentation of interactions with
patients is a prudent risk-management
strategy. Documentation of the details of
consent discussions in the lead-up to
surgical procedures is particularly impor-
tant, as the vast majority of informed
consent disputes involve complications
following operations [2,11].
Despite their rarity, disputed duty cases
are of special interest for several reasons.
From a legal standpoint, these are the
types of cases that define and test the
standard of care to which doctors must
adhere in obtaining informed consent.
From a medical standpoint, the clinical
details of disputed duty cases may point to
an important ‘‘penumbra’’ of treatment
risks—outcomes about which there is
division or uncertainty among doctors as
Table 2. Doctors’ justifications for non-disclosure of risk in disputed duty cases.
Justification Type n (%) Case Examples
Treatment and Health Outcome Excerpts from Doctors’ Justificatory Statements
Rare risk 18 (40%) Cyclosporin leading to tinnitus
and hearing loss
Rectal prolapse repair leading to
inability to ejaculate
‘‘It is not our practice to mention all rarely reported side-
effects of every medication that is prescribed.’’
‘‘I would not specifically have warned of potential sexual
difficulties because the incidence should be relatively
low.’’
Subset of general risk 11 (24%) Migration of gastric reflux collar
leading to cardiac tamponade
Phenytoin leading to Stevens-Johnson
syndrome causing blindness
‘‘I had mentioned Angelchik collars had been known to
migrate. I had certainly not mentioned this exceedingly
rare complication.’’
‘‘I did not warn him specifically of Stevens Johnson
syndrome though I did discuss allergic reactions in
general.’’
Obvious or implied risk 5 (11%) Cosmetic eyelid surgery leading
to post-operative infection
‘‘Although I may not have highlighted problems of
infection, most people, particularly if they are married to a
doctor, would be aware that any operation can be
complicated by infection.’’
Duration of risk 4 (9%) Cosmetic breast surgery with poor
wound healing after one year
‘‘Most would be healed within a couple of months. The
maximum time I would have expected would be six
months.’’
Risk clearly outweighed by benefits 4 (9%) Abdominal lipectomy leading to
post-operative infection and scarring
‘‘Infection is a solvable problem and the patient would still
be in a better position than before the surgery.’’
Risk of negligence 3 (7%) Gastric lap band leading to perforation
of right ventricle by liver retractor
‘‘I did not mention specifically perforation of the heart, but
this could be understood as this has never been reported
before.’’
doi:10.1371/journal.pmed.1001283.t002
Table 1. Physical health outcomes associated with undisclosed risks that materialised in disputed duty cases.
Outcomes n (%)
a
Further surgery required 15 (33%)
Chronic pain 13 (29%)
Poor cosmetic result or delayed wound healing 9 (20%)
Impaired vision or hearing 8 (18%)
Infertility or sexual dysfunction 7 (16%)
Paralysis 3 (7%)
Other 12 (27%)
aTotal sums to greater than 45 because categories are not mutually exclusive.
doi:10.1371/journal.pmed.1001283.t001
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warning. From a patient standpoint,
disputed duty cases may highlight certain
types of risks that patients tend to prioritise
more highly than doctors do. What lessons
does an analysis of such cases have for how
doctors should approach the informed
consent process?
What to Disclose: A Balancing
Act
The clinical reality is that standardised
consent forms are widely used, particularly
for common procedures, and they tend to
present exhaustive enumerations of risks.
Anglo-American courts do not accept that
merely handing such forms to patients as a
valid way to obtain informed consent.
Consequently, clinicians must determine
which risks to discuss and emphasise. For
busy doctors this necessitates choices because
time is limited and effort devoted to consent
discussions has opportunity costs [17].
One approach is to focus discussion on
risks of outcomes above a certain inci-
dence. The notion of a 1% risk threshold
appears to have some currency in clinical
practice. However, it has no firm basis in
either law or available evidence regarding
patients’ attitudes to risk [18,19,20].
Courts regard the probability of a partic-
ular adverse outcome as an important
element in determining what qualifies as a
‘‘material’’ risk that must be disclosed, but
it is one of several elements.
The severity of the outcome associated
with a risk also matters. It is reasonable to
think of rarity and severity as consider-
ations that operate in tandem, on a sliding
scale. Small risks of catastrophic outcomes
usually warrant emphasis, as do high risks
of relatively minor adverse outcomes, but
not low risks of minor outcomes.
Distinctive characteristics of individual
patients may also dictate the breadth and
depth of discussion about certain risks; the
extreme example of a hand operation on a
concert pianist helps to illustrate the point. A
less obvious consideration is the treatment’s
urgency. Details of risks tend to matter more
toward the elective end of the treatment
spectrum than the urgent or emergent end,
which may help to explain the prominence of
cosmetic treatments among the disputed duty
cases in our sample.
To this recognised set of factors, our
analysis draws attention to five outcomes
that appear to trigger the majority of
disputed duty cases—the need for further
surgery, poor cosmesis, impaired vision or
hearing, chronic pain, and infertility or
sexual dysfunction. These are outcomes
that clinicians may give too little weight
and attention in the consent process.
Limitations
Our analysis has several limitations.
First, we examined legal disputes over
the duty to disclose certain risks; this
sample of cases may be unrepresentative
of wider disagreements between patients
and doctors in this area because they are
refracted through the lens of patients’
claiming and complaining behaviour
[21]. Second, we were constrained by
the information set available in claim
and complaint files. Finally, the gener-
alisability of our findings may be influ-
enced by differences in medico-legal
systems and, in particular, the prevailing
legal standard for informed consent.
Since 1992, Australian courts have
applied a patient-centred standard
[5,22]; the same standard prevails in
around half of the states in the US [2]
and in a number of other countries
[4,6,7,8], where the decision in Canterbury
vS p e n c ehas proved to be influential.
Conclusion
The rationale for informed consent
springs from the ethical principle of
autonomy—the notion that it is patients
themselves who should make the final
decision about which course of treatment
to follow. Increasingly, doctors are expect-
ed to advise and empower patients to
make rational choices by sharing informa-
tion that may bear upon the decision,
including risks of undesired outcomes.
Occasionally, doctors and patients will
disagree about whether a particular risk
has an important bearing on treatment
choices. Improved understanding of these
situations helps to spotlight gaps between
Table 3. Characteristics of 18 disputed duty cases in which doctors’ justification for non-disclosure was risk too rare.
Treatment Risk That Materialised Probability of Risk
Topical steroid for eczema Steroid induced rosacea .1% [23]
Rectal prolapse repair Inability to ejaculate .1% [24]
Caesarean for breech baby Fetal laceration requiring surgical repair .1% [25,26]
Prolonged prednisone for erythematous eruptions Avascular necrosis requiring hip replacement .1% [27]
Laparoscopy for endometriosis Removal of ovary and tube to control bleeding 0.1 to 1% [28]
Cyclosporin for psoriasis Tinnitus and hearing loss 0.1 to 1% [29]
Inguinal hernia repair Testicular necrosis requiring orchidectomy 0.1 to 1% [30]
Spinal anaesthetic for caesarean Paraesthesia and weakness in leg 0.01 to 0.1% [31]
Laryngeal mask airway Loose teeth requiring dental surgery 0.01 to 0.1% [32,33]
Laparoscopic gastric banding Cuff leak after 15 months requiring surgery to replace band 0.01 to 0.1% [34]
Flucloxacillin Hepatitis ,0.01% [35]
Bilateral inguinal hernia repair Infertility due to azoospermia ,0.01% [36,37]
Vaginal delivery of 4.5 kg baby Diastasis of symphysis pubis ,0.01% [38]
Varicocoele repair Testicular infarct requiring orchidectomy Case reports [39]
Vasectomy Sperm granuloma requiring surgical excision Case reports [40]
Coronary angiogram and angioplasty Damage to aortic valve requiring emergency cardiac surgery Not available
Dilatation/washout of tear ducts Lacrimal duct stenosis leading to inflammation and impaired vision Not available
Pelvic osteotomy for scoliosis Cosmetic deformity (prominent lateral hip) Not available
doi:10.1371/journal.pmed.1001283.t003
PLOS Medicine | www.plosmedicine.org 5 August 2012 | Volume 9 | Issue 8 | e1001283what patients want to hear and what
doctors perceive patients want (or should
want) to hear. It may also be useful
information for doctors eager to avoid
medico-legal disputes.
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